NCT04989699View on ClinicalTrials.gov

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

December 18, 2023

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

OTX-TKI/Sham

OTX-TKI is one dose so subsequent visits will be sham to maintain the mask

DRUG

Aflibercept/Sham

Aflibercept administered every 8 weeks

Trial Locations (6)

32701

Ocular Therapeutix, Altamonte Springs

33711

Ocular Therapeutix, St. Petersburg

77384

Ocular Therapeutix, The Woodlands

89502

Ocular Therapeutix, Reno

93036

Ocular Therapeutix, Oxnard

93309

Ocular Therapeutix, Bakersfield

Sponsors
All Listed Sponsors
lead

Ocular Therapeutix, Inc.

INDUSTRY